Oligodendroglioma - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 90 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Oligodendroglioma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Oligodendroglioma - Pipeline Review, H2 2014', provides an overview of the Oligodendroglioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oligodendroglioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oligodendroglioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oligodendroglioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Oligodendroglioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Oligodendroglioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Oligodendroglioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Oligodendroglioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Oligodendroglioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Oligodendroglioma Overview 8
Therapeutics Development 9
Pipeline Products for Oligodendroglioma - Overview 9
Pipeline Products for Oligodendroglioma - Comparative Analysis 10
Oligodendroglioma - Therapeutics under Development by Companies 11
Oligodendroglioma - Therapeutics under Investigation by Universities/Institutes 12
Oligodendroglioma - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Oligodendroglioma - Products under Development by Companies 15
Oligodendroglioma - Products under Investigation by Universities/Institutes 16
Oligodendroglioma - Companies Involved in Therapeutics Development 17
Cavion LLC 17
Celgene Corporation 18
Celldex Therapeutics, Inc. 19
Eli Lilly and Company 20
F. Hoffmann-La Roche Ltd. 21
Novartis AG 22
Orbus Therapeutics, Inc. 23
Sanofi 24
Takeda Oncology 25
Tocagen Inc. 26
Oligodendroglioma - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
alisertib - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
bevacizumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CC-122 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Cell Therapy for Gliomas - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Dendritic Cell Therapy for Oncology - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
DNX-2401 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
eflornithine hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
galunisertib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
mibefradil dihydrochloride - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
panobinostat - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
plerixafor - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
rindopepimut - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Stem Cell Therapy for Glioma - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Oligodendroglioma - Recent Pipeline Updates 72
Oligodendroglioma - Dormant Projects 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 90
Disclaimer 90

List of Tables
Number of Products under Development for Oligodendroglioma, H2 2014 9
Number of Products under Development for Oligodendroglioma - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Oligodendroglioma - Pipeline by Cavion LLC, H2 2014 17
Oligodendroglioma - Pipeline by Celgene Corporation, H2 2014 18
Oligodendroglioma - Pipeline by Celldex Therapeutics, Inc., H2 2014 19
Oligodendroglioma - Pipeline by Eli Lilly and Company, H2 2014 20
Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 21
Oligodendroglioma - Pipeline by Novartis AG, H2 2014 22
Oligodendroglioma - Pipeline by Orbus Therapeutics, Inc., H2 2014 23
Oligodendroglioma - Pipeline by Sanofi, H2 2014 24
Oligodendroglioma - Pipeline by Takeda Oncology, H2 2014 25
Oligodendroglioma - Pipeline by Tocagen Inc., H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Assessment by Combination Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 36
Oligodendroglioma Therapeutics - Recent Pipeline Updates, H2 2014 72
Oligodendroglioma - Dormant Projects, H2 2014 88